Your browser is no longer supported. Please, upgrade your browser.
Settings
CLRB Cellectar Biosciences, Inc. daily Stock Chart
CLRB [NASD]
Cellectar Biosciences, Inc.
Index- P/E- EPS (ttm)-0.35 Insider Own2.20% Shs Outstand12.49M Perf Week-0.85%
Market Cap29.10M Forward P/E- EPS next Y-0.85 Insider Trans117.91% Shs Float11.72M Perf Month5.91%
Income-6.20M PEG- EPS next Q-0.23 Inst Own11.60% Short Float10.04% Perf Quarter92.56%
Sales- P/S- EPS this Y80.60% Inst Trans83.90% Short Ratio1.19 Perf Half Y-16.19%
Book/sh1.68 P/B1.39 EPS next Y5.60% ROA-59.50% Target Price5.27 Perf Year-41.16%
Cash/sh0.91 P/C2.55 EPS next 5Y- ROE-75.40% 52W Range1.00 - 5.05 Perf YTD90.98%
Dividend- P/FCF- EPS past 5Y53.40% ROI- 52W High-53.86% Beta0.42
Dividend %- Quick Ratio7.50 Sales past 5Y- Gross Margin- 52W Low133.00% ATR0.25
Employees15 Current Ratio7.50 Sales Q/Q- Oper. Margin- RSI (14)52.17 Volatility9.44% 10.01%
OptionableNo Debt/Eq0.01 EPS Q/Q-131.00% Profit Margin- Rel Volume0.42 Prev Close2.27
ShortableYes LT Debt/Eq0.00 EarningsMar 14 AMC Payout- Avg Volume989.79K Price2.33
Recom1.00 SMA20-2.57% SMA5015.30% SMA2002.06% Volume413,955 Change2.64%
Dec-21-16Initiated Ladenburg Thalmann Buy $2.70
Mar-21-17 04:04PM  CELLECTAR BIOSCIENCES, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
01:04PM  CELLECTAR BIOSCIENCES, INC. Financials
08:30AM  Cellectar Biosciences Further Deepens Intellectual Property Portfolio with Patent Grant for PET Imaging PDC GlobeNewswire
Mar-16-17 03:57PM  Edited Transcript of CLRB earnings conference call or presentation 15-Mar-17 10:00pm GMT -7.00%
08:31AM  CELLECTAR BIOSCIENCES, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
Mar-15-17 06:00PM  Cellectar Biosciences Inc Earnings Call scheduled for 6:00 pm ET today
04:15PM  Cellectar Biosciences Reports 2016 Company Performance and Continued Progress in First Quarter 2017 GlobeNewswire
09:03AM  CELLECTAR BIOSCIENCES, INC. Files SEC form 10-K, Annual Report
Mar-14-17 04:05PM  CELLECTAR BIOSCIENCES, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
02:15PM  Cellectar Biosciences Secures Japanese Patent at Investopedia
08:30AM  Newly Issued Japanese Patent For PDC Optical Agents Further Strengthens Cellectar Biosciences Intellectual Property Portfolio GlobeNewswire
Mar-09-17 05:24PM  CELLECTAR BIOSCIENCES, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
08:30AM  Cellectar Biosciences to Host Conference Call on March 15 to Report Fourth Quarter and Year-End 2016 Financial Results and Corporate Performance GlobeNewswire
Mar-08-17 04:03PM  CELLECTAR BIOSCIENCES, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits +7.38%
08:00AM  Expanding Its Strategic Relationship with Wisconsin Alumni Research Foundation (WARF), Cellectar Biosciences Executes New License Agreement GlobeNewswire
Mar-06-17 04:02PM  CELLECTAR BIOSCIENCES, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits +7.21%
08:30AM  Cellectar Biosciences to Present at 29th Annual Roth Conference GlobeNewswire
Feb-27-17 04:09PM  CELLECTAR BIOSCIENCES, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
08:00AM  Cellectar Biosciences Provides Phase I Trial Update of CLR 131 in Multiple Myeloma: Median Progression-Free Survival Extends to 133 Days, Median Overall Survival Reaches 17.7 Months GlobeNewswire
Feb-22-17 04:02PM  CELLECTAR BIOSCIENCES, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits -5.41%
08:30AM  Upon Successful Completion of Cohort 3, Cellectar Biosciences Initiates Fourth Cohort of Its Phase I Clinical Trial of CLR 131 in Multiple Myeloma GlobeNewswire
Feb-13-17 03:54PM  Cellectar Biosciences' PDC Delivery Platform May Advance Treatment of Multiple Myeloma
07:00AM  UPDATE -- Cellectar Biosciences to Present at 2017 BIO CEO & Investor Conference GlobeNewswire
Feb-10-17 06:12AM  CELLECTAR BIOSCIENCES, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
Feb-09-17 08:30AM  Cellectar Biosciences to Present at the 2nd Annual Disruptive Growth & Healthcare Conference Accesswire +13.66%
Feb-07-17 04:03PM  CELLECTAR BIOSCIENCES, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
08:30AM  Cellectar Biosciences to Present at 2017 BIO CEO & Investor Conference GlobeNewswire
Feb-03-17 05:01PM  CELLECTAR BIOSCIENCES, INC. Files SEC form 8-K, Other Events
Jan-31-17 04:08PM  CELLECTAR BIOSCIENCES, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
08:30AM  Cellectar Biosciences Announces Two Peer Reviewed Studies Demonstrating the Capabilities of the PDC Platform GlobeNewswire
Jan-26-17 04:02PM  CELLECTAR BIOSCIENCES, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
08:30AM  Cellectar Biosciences to Present at NobleCon13 GlobeNewswire
Jan-25-17 11:48AM  Cellectar Biosciences Secures Cancer Drug Patent at Investopedia
Jan-24-17 04:02PM  CELLECTAR BIOSCIENCES, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits +12.32%
08:30AM  Cellectar Biosciences Announces Additional US Patent Granted for CLR 131 and CLR 125 in a Broad Range of Solid Tumors GlobeNewswire
Jan-05-17 04:03PM  CELLECTAR BIOSCIENCES, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
08:30AM  Cellectar Biosciences to Present at the 9th Annual Biotech Showcase GlobeNewswire
Dec-21-16 06:59AM  Coverage initiated on Cellectar Biosciences by Ladenburg Thalmann
Dec-20-16 04:03PM  CELLECTAR BIOSCIENCES, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
08:30AM  Cellectar Biosciences Announces US and Japanese Patent Allowances for Diagnostic and Optical Imaging PDCs GlobeNewswire
Dec-19-16 04:02PM  CELLECTAR BIOSCIENCES, INC. Files SEC form 8-K, Other Events -6.20%
Dec-14-16 04:02PM  CELLECTAR BIOSCIENCES, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits -6.06%
08:30AM  Cellectar Biosciences Announces USPTO Grants Patent Allowances for Radiotherapeutic PDCs for A Variety of Solid Tumor Types GlobeNewswire
Dec-12-16 04:02PM  CELLECTAR BIOSCIENCES, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
08:30AM  Cellectar Biosciences Announces USPTO Grants Patent for Paclitaxel PDC; Provides Additional Patent Protection for Select Solid Tumors Through 2035 GlobeNewswire
Dec-09-16 04:07PM  CELLECTAR BIOSCIENCES, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement
Dec-06-16 04:08PM  CELLECTAR BIOSCIENCES, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
08:30AM  Cellectar Biosciences Presents Poster at the 58th Annual Meeting of the American Society of Hematology GlobeNewswire
Dec-01-16 04:09PM  CELLECTAR BIOSCIENCES, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
08:00AM  Cellectar Biosciences Announces Results From the First Two Cohorts of Its CLR 131 Phase 1 Trial: Demonstrates Excellent Efficacy, Overall Survival Benefit, and Progression Free Survival Similar to or Better than Recently Approved Therapies GlobeNewswire
Nov-30-16 04:33PM  CELLECTAR BIOSCIENCES, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Regulation FD Disclosure, -5.16%
Nov-29-16 06:40PM  Cellectar Biosciences Announces Successful Completion of $9.2 Million Public Offering, Which Includes Full Exercise of $1.2 Million Over-Allotment Option GlobeNewswire
Nov-28-16 04:05PM  CELLECTAR BIOSCIENCES, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
08:00AM  Cellectar Biosciences Announces Partnership with Radiopharmaceutical Specialists, CPDC, to Establish Manufacturing Capacity in Anticipation of CLR 131 Pivotal Trial and Commercial Production GlobeNewswire
Nov-23-16 11:47AM  Cellectar Biosciences (CLRB), Juno Therapeutics (JUNO), Newmont Mining (NEM) and More: What is Going on With These Falling Stocks? at Insider Monkey -31.02%
08:30AM  Cellectar Biosciences Announces Pricing of $8,000,000 Public Offering GlobeNewswire
Nov-17-16 04:03PM  CELLECTAR BIOSCIENCES, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
10:11AM  Movers In Biotech: Cellectar Biosciences Inc (CLRB) And The Medicines Company (MDCO) at Insider Monkey
08:00AM  Cellectar Biosciences Announces Successful Conjugation of Multiple Pierre Fabre Cytotoxic Compounds to PDC Delivery Platform; Initiates In Vivo Studies for Solid Tumors GlobeNewswire
Nov-16-16 09:00AM  SeeThruEquity Issues Update on Cellectar Biosciences, Inc. (NASDAQ:CLRB) Accesswire +12.77%
Nov-15-16 10:00AM  Cellectar Biosciences Announces INC Research as the CRO for the Phase II Trial of CLR 131 in Hematologic Malignancies; $2M NCI Grant Covers Half of Study Cost, with Potential Option to Pursue Additional $3M for Pivotal Trial GlobeNewswire +26.34%
Nov-11-16 07:05PM  Cellectar Biosciences Inc (CLRB) Is Oversold And Ready To Bounce Higher at Insider Monkey +7.34%
01:50PM  UPDATE -- Cellectar Biosciences Announces Recent Key Accomplishments and Third Quarter 2016 Financial Results GlobeNewswire
Nov-10-16 04:32PM  CELLECTAR BIOSCIENCES, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
04:15PM  Cellectar Biosciences Announces Recent Key Accomplishments and Third Quarter 2016 Financial Results GlobeNewswire
04:05PM  CELLECTAR BIOSCIENCES, INC. Files SEC form 10-Q, Quarterly Report
Nov-07-16 04:07PM  CELLECTAR BIOSCIENCES, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
08:30AM  Cellectar Biosciences to Host Conference Call on November 11 to Report Third Quarter 2016 Financial Results and Corporate Performance GlobeNewswire
Oct-31-16 04:16PM  CELLECTAR BIOSCIENCES, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits +6.32%
09:45AM  Cellectar Biosciences Announces Design for NCI-Supported Phase II Study of CLR 131 in Multiple Myeloma and Other Hematologic Malignancies GlobeNewswire
Oct-24-16 05:05PM  CELLECTAR BIOSCIENCES, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits -10.29%
08:30AM  Cellectar Biosciences Announces Data on CLR 131 Accepted For Poster Presentation at the 58th Annual American Society of Hematology Meeting & Exposition GlobeNewswire
Oct-13-16 08:30AM  Cellectar Biosciences To Present at BIO Investor Forum GlobeNewswire
Oct-11-16 08:30AM  Cellectar Biosciences To Present at SeeThru Equity and Dawson James Investor Conferences GlobeNewswire
Oct-06-16 04:12PM  CELLECTAR BIOSCIENCES, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
08:30AM  Cellectar Biosciences Announces Enrollment of First Patient into Third Cohort of Its Phase I Clinical Study of CLR 131 in Multiple Myeloma GlobeNewswire
Oct-05-16 06:08AM  CELLECTAR BIOSCIENCES, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
Oct-04-16 08:30AM  Cellectar Biosciences Announces USPTO Issues Formal Patent Allowance for CLR 1603 GlobeNewswire
Sep-29-16 04:03PM  CELLECTAR BIOSCIENCES, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
08:30AM  Cellectar Biosciences Announces New Positive Data from Phase I Clinical Study of CLR 131 in Multiple Myeloma GlobeNewswire
Sep-21-16 08:30AM  Cellectar Biosciences To Present at OktoberINVESTfest GlobeNewswire
Sep-19-16 08:30AM  Cellectar Biosciences to Present at Ladenburg Thalmann 2016 Healthcare Conference GlobeNewswire
Sep-12-16 04:02PM  CELLECTAR BIOSCIENCES, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
08:30AM  Cellectar Biosciences Announces Lead Compound CLR 131 To Be Studied In Head and Neck Cancer in $12M University of Wisconsin SPORE Grant GlobeNewswire
Sep-06-16 08:30AM  Cellectar Biosciences To Present at the 18th Annual Rodman & Renshaw Global Investment Conference GlobeNewswire +6.94%
Aug-18-16 09:00AM  SeeThruEquity Issues Update on Cellectar Biosciences, Inc. (Nasdaq: CLRB) Accesswire
Aug-17-16 11:06AM  Edited Transcript of CLRB earnings conference call or presentation 15-Aug-16 12:30pm GMT
Aug-12-16 04:03PM  CELLECTAR BIOSCIENCES, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits +10.07%
03:25PM  UPDATE -- Cellectar Biosciences Announces Recent Key Accomplishments and Second Quarter 2016 Financial Results GlobeNewswire
Aug-11-16 04:45PM  Cellectar Biosciences Announces Recent Key Accomplishments and Second Quarter 2016 Financial Results GlobeNewswire
04:06PM  CELLECTAR BIOSCIENCES, INC. Files SEC form 10-Q, Quarterly Report
07:50AM  Medical Product Stock Earnings Coming Up: IMMY, OMCM, CLRB
Aug-09-16 04:03PM  CELLECTAR BIOSCIENCES, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
Aug-08-16 08:30AM  Cellectar Biosciences to Host Conference Call on August 15 to Report Second Quarter 2016 Financial Results and Corporate Performance GlobeNewswire
Aug-03-16 08:00AM  Cellectar Biosciences Announces $2 Million NCI SBIR Contract for a Phase 2 Clinical Study GlobeNewswire +6.69%
Jul-27-16 04:04PM  CELLECTAR BIOSCIENCES, INC. Files SEC form 8-K, Changes in Registrant's Certifying Accountant +8.24%
Jul-21-16 08:30AM  StockNewsNow.com Publishes New SNNLive Video Interview with Cellectar Biosciences, Inc. Discussing Corporate Updates and Clinical Development PR Newswire
Jul-20-16 04:03PM  CELLECTAR BIOSCIENCES, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Regulation FD Disclosure,
08:30AM  Cellectar Biosciences Appoints Jarrod Longcor Senior Vice President of Corporate Development and Operations GlobeNewswire
Jul-18-16 09:00AM  SeeThruEquity Initiates Coverage on Cellectar Biosciences, Inc. (NASDAQ: CLRB) with a Price Target of $7.44 Accesswire -10.24%
Cellectar Biosciences, Inc., a clinical stage biopharmaceutical company, engages in the development of targeted phospholipid drug conjugates (PDCs) for the treatment and imaging of cancer. It offers CLR 131, a PDC radiotherapeutic product candidate and is currently being evaluated in a Phase I study for the treatment of relapse or refractory multiple myeloma; CLR 125, a cancer-targeting radiotherapeutic is under pre-clinical investigation for the treatment of micrometastatic disease ; CLR 124, a cancer-targeting positron emission tomography (PET) imaging PDC for the selective detection of tumors and metastases in a broad range of cancers; and CLR 1502, a cancer-targeting NIR-fluorophore optical imaging PDC for intraoperative tumor and tumor margin illumination. The company was formerly known as Novelos Therapeutics, Inc. and changed its name to Cellectar Biosciences, Inc. in February 2014. Cellectar Biosciences, Inc. was founded in 2002 and is headquartered in Madison, Wisconsin.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
NEIS JOHNDirectorNov 29Buy1.49333,333496,666631,317Nov 30 06:59 PM